Innate Pharma specializes in immuno oncology, a new therapeutic field that is changing cancer treatment by enhancing the capability of the body s own immune cells to recognize and kill cancer cells. The Company has pioneered the development of antibodies that block inhibitory checkpoint receptors on NK cells. Today, Innate Pharma has three first in class antibodies in clinical development in immuno oncology and a pipeline of preclinical candidates to novel targets and mechanisms. Its innovative approach has translated into alliances with leaders in the biopharmaceutical industry such as AstraZeneca, Bristol Myers Squibb, Novo Nordisk A/S and Sanofi. Based in Marseille, France, Innate Pharma had employees as at March , . The company is listed on Euronext Paris.
Quote | Innate Pharma (OTCMKTS:IPHYF)
Last: | $2.65 |
---|---|
Change Percent: | 8.3% |
Open: | $2.43 |
Close: | $2.65 |
High: | $2.65 |
Low: | $2.43 |
Volume: | 300 |
Last Trade Date Time: | 04/02/2024 03:00:00 am |
News | Innate Pharma (OTCMKTS:IPHYF)
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) will hold its Annual General Meeting of Shareholders (“ AGM ”) at 10:30 a.m. CEST on May 23, 2024 in its headquarters, 117 avenue de Lumi...
Partner Sanofi advances SAR443579 / IPH6101, ANKET ® platform lead asset, a trifunctional anti-CD123 NKp46xCD16 NK cell engager, to Phase 2 dose expansion in blood cancers Dosing of the first patient in the dose expansion part of the trial triggers a €4m milestone paym...
Message Board Posts | Innate Pharma (OTCMKTS:IPHYF)
Subject | By | Source | When |
---|---|---|---|
Stock_Tracker: Latest Innate Pharma (IPHYF) Headlines INNATE PHARMA : raises 20.3 million in a | Stock_Tracker | investorshangout | 03/10/2014 10:53:12 AM |
chartguy89: IPHYF 15.058 Stock Charts $IPHYF 1 Month Chart | chartguy89 | investorshangout | 03/08/2014 4:38:31 AM |
chartguy89: IPHYF Stock Charts Last: -0.78 Thursday, February 27, 2014 at 3:45:56 AM $IPHYF | chartguy89 | investorshangout | 02/27/2014 8:46:08 AM |
News, Short Squeeze, Breakout and More Instantly...
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) will hold its Annual General Meeting of Shareholders (“ AGM ”) at 10:30 a.m. CEST on May 23, 2024 in its headquarters, 117 avenue de Lumi...
Partner Sanofi advances SAR443579 / IPH6101, ANKET ® platform lead asset, a trifunctional anti-CD123 NKp46xCD16 NK cell engager, to Phase 2 dose expansion in blood cancers Dosing of the first patient in the dose expansion part of the trial triggers a €4m milestone paym...
IPH45 is a novel and differentiated exatecan-Antibody Drug Conjugate targeting Nectin-4 In PDX models of urothelial tumors, IPH45 has stronger activity than approved Nectin-4 targeting EV. IPH45 shows anti-tumor efficacy in various solid tumor and EV-refractory models Prec...